Abstract: A transmission (G) for a motor vehicle includes a pump (P), an oil sump (S), a hydraulic control unit (HCU), a gear set (RS) for providing different transmission ratios between an input shaft (GW1) and an output shaft (GW2) of the transmission (G), and a cavity (HY) arranged on an input side, in which a torque converter (TC) and/or an electric machine (EM) are accommodated. The cavity (HY) is connected to the oil sump (S) via a gap (C) configured for a passive return of oil out of the cavity (HY) into the oil sump (S). In order to reduce the gap (C), a separating element (T) is configured for making it difficult for oil to flow out of the oil sump (S) to the cavity (HY). A drive train comprising such a transmission (G) is also provided.

Abstract: A transmission (G) for a motor vehicle includes a pump (P), an oil sump (S), a hydraulic control unit (HCU), a gear set (RS) for providing different transmission ratios between an input shaft (GW1) and an output shaft (GW2) of the transmission (G), and a cavity (HY) arranged on an input side, in which a torque converter (TC) and/or an electric machine (EM) are accommodated. The cavity (HY) is connected to the oil sump (S) via a gap (C) configured for a passive return of oil out of the cavity (HY) into the oil sump (S). In order to reduce the gap (C), a separating element (T) is configured for making it difficult for oil to flow out of the oil sump (S) to the cavity (HY). A drive train comprising such a transmission (G) is also provided.

Abstract: A greaser for a transmission includes a shaft (1) having an axial bore (3) and a plurality of axially spaced radial bores (6a, 6b, 6c). Each of at least one tube (8a, 8b) is inserted into a respective one of the axially spaced radial bores (6a, 6b) and extends radially inwardly into the axial bore (3) beyond a circumferential surface (4) of the axial bore (3) that is adjacent the respective one of the axially spaced radial bores (6a, 6b). Each of the at least one tube (8a, 8b) includes a slot (11a, 11b) at a tube end (10a, 10b) facing a central axis (2) of the shaft (1). The slot (11a, 11b) of each of the at least one tube (8a, 8b) extends along a central axis (9a, 9b) of the respective tube (8a, 8b) into an interior space of the axial bore (3).

Abstract: A drag torque reduction device for an automatic transmission includes a hydraulic controller with a radiator. In one embodiment, the drag torque reduction device also includes a parallel connection of a pressure relief valve, a constant aperture and a temperature-dependent, switchable aperture positioned upstream of the radiator. In another embodiment, the drag torque reduction device includes an overflow cooling oil diversion with a temperature-dependent, switchable aperture and a pressure relief valve that is positioned upstream of the radiator.

Abstract: A greaser for a transmission includes a shaft (1) having an axial bore (3) and a plurality of axially spaced radial bores (6a, 6b, 6c). Each of at least one tube (8a, 8b) is inserted into a respective one of the axially spaced radial bores (6a, 6b) and extends radially inwardly into the axial bore (3) beyond a circumferential surface (4) of the axial bore (3) that is adjacent the respective one of the axially spaced radial bores (6a, 6b). Each of the at least one tube (8a, 8b) includes a slot (11a, 11b) at a tube end (10a, 10b) facing a central axis (2) of the shaft (1). The slot (11a, 11b) of each of the at least one tube (8a, 8b) extends along a central axis (9a, 9b) of the respective tube (8a, 8b) into an interior space of the axial bore (3).

Abstract: A drag torque reduction device for an automatic transmission includes a hydraulic controller with a parallel connection of a pressure relief valve, a constant aperture and a temperature-dependent, switchable aperture that is positioned upstream of a radiator relative to a flow of fluid to the radiator. The parallel connection is disposed between a first control edge of a converter switching valve and a first line. The first line leads to both to the radiator and through a check valve to the converter ring. The first control edge of the converter switching valve is open and lubricating oil flows through the parallel connection when the converter switching valve is in a first switching position. The first control edge of the converter switching valve is closed and lubricating oil does not flow through the parallel connection when the converter switching valve is in a second switching position.

Abstract: A drag torque reduction device for an automatic transmission includes a hydraulic controller with a diversion for excess cooling oil into an oil sump that is positioned upstream of a radiator relative to a flow of fluid to the radiator. The diversion includes a temperature-dependent, switchable aperture and a switching valve. The temperature-dependent, switchable aperture is configured to close above a temperature threshold. The switching valve is configured to close above a threshold pressure.

Abstract: A drag torque reduction device for an automatic transmission includes a hydraulic controller with a radiator. In one embodiment, the drag torque reduction device also includes a parallel connection of a pressure relief valve, a constant aperture and a temperature-dependent, switchable aperture positioned upstream of the radiator. In another embodiment, the drag torque reduction device includes an overflow cooling oil diversion with a temperature-dependent, switchable aperture and a pressure relief valve that is positioned upstream of the radiator.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Abstract: Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence: R1-X01-X02-X03-X04-X05-X06-X07-X08-X09-X10-X11-X12-X13-R2. These peptides have a high affinity for immunoglobulins. Applications of the peptides according to the invention are also described.

Abstract: A method of producing a connection between an outer joint part of a constant velocity universal joint and a shaft journal, wherein the shaft journal is provided with a flange which is co-axially attached to the outer joint part, wherein a tubular sleeve with a greater diameter is slid at a radial distance over the butt joint between the outer joint part and the flange and wherein the tubular sleeve is reduced radially by a pulse welding process and welded to the outer joint part and to the flange.

Abstract: Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence: